Entrepreneurs, and Earning the Trust of
Investors Through Science, Strategy, and
Innovation.
/ WHO WE ARE
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
8
FUNDS
Since 2000
/ EXPERT INSIGHT
ST. LOUIS (May 15, 2026) –
RiverVest Principal Pascal Krotee discusses the underlying biology of a devastating neurodegenerative disease and how advances in RNA biology are reshaping what may be possible, opening the door to interventions that could meaningfully alter its course.
/ EXPERT INSIGHT
RiverVest Managing Director Isacc Zike shares key insights from JPM 2026 – the largest and most informative healthcare investment symposium in the industry.
/ ACQUISITION
Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals
ST. LOUIS (December 8, 2025) – Bluejay Therapeutics – a RiverVest Venture Fund V portfolio company – has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a former RiverVest portfolio company focusing on rare liver diseases.
30
COMMERCIAL PRODUCTS
Currently Treating Patients
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2026 RiverVest® All Rights Reserved. | Privacy Policy | Accessibility Statement
Subscribe to our newsletter